Connecticut
Fee-For-Service Medicaid Coverage of Screening
Covered and Using Updated Guidelines
Highlighted Disparity
Asian or Pacific Islander individuals in Connecticut are least likely to be diagnosed early.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 55.6 and not significantly different than the national rate of 54.6.
- Connecticut ranks 22nd among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Connecticut has improved by 22%
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Connecticut is 33.1%, which is significantly higher than the national rate of 26.6%.
- It ranks 2nd among the 42 states with survival data, placing it in the top tier.
- Over the last five years, the survival rate in Connecticut improved by 25%.
Early Diagnosis:
- 32.3% of cases are caught at an early stage, which is significantly higher than the national rate of 26.6%.
- It ranks 2nd among the 47 states with data on diagnosis at an early stage, placing it in the top tier.
- Over the last five years, the early diagnosis rate in Connecticut did not change signficantly.
Lung Cancer Treatment
Surgical Treatment:
- Connecticut ranked 6th (out of the 47 states with available data) with 25.1% of cases undergoing surgery as part of the first course of treatment.
- This is significantly higher than the national rate of 20.8% and puts Connecticut in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in Connecticut improved by -18%
Lack of Treatment:
- Connecticut ranked 9th (out of the 47 states with available data) with 17.1% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.6% and puts Connecticut in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in Connecticut did not change significantly.
Screening
Screening for High Risk:
- In Connecticut, 5.9% of those at high risk were screened, which was significantly higher than the national rate of 4.5%.
- It ranks 19th among all states, placing it in the average tier.
- Actual screening rates may be higher in states with large, regional managed care providers that did not share screening data.
Medicaid Coverage:
- Connecticut was one of the 49 states whose Medicaid fee-for-service programs covered lung cancer screening as of October 2023.
- While their program did not require prior authorization or copays, it did not use recommended guidelines for determining eligibility.
Prevention
Tobacco Use:
- The smoking rate in Connecticut is 11.1% and significantly lower than the national rate of 13.5%.
- It ranks 9th among all states, placing it in the above average tier.
Radon:
- In Connecticut, 25.8% of radon tests results were at or above the action level recommended by EPA.
- It ranks 29th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 53.8 per 100,000 population among Black individuals in Connecticut, not significantly different than the rate of 56.3 among Black individuals nationally, and significantly lower than the rate of 58.2 among white individuals in Connecticut.
- The five-year survival rate is 33.2% among Black individuals in Connecticut, significantly higher than the rate of 23.8% among Black individuals nationally, and not significantly different than the rate of 32.9% among white individuals in Connecticut.
- 28.3% of lung cancer cases are diagnosed at an early stage among Black individuals in Connecticut, significantly higher than the rate of 23.2% among Black individuals nationally, and significantly lower than the rate of 32.9% among white individuals in Connecticut.
- 22.4% of Black individuals with lung cancer in Connecticut underwent surgery, significantly higher than the rate of 17.0% among Black individuals nationally, and not significantly different than the rate of 25.1% among white individuals in Connecticut.
- 18.2% of Black individuals with lung cancer in Connecticut did not receive any treatment, significantly lower than the rate of 22.4% among Black individuals nationally, and not significantly different than the rate of 17.2% among white individuals in Connecticut.
Latino individuals:
- The rate of new lung cancer cases is 38.8 per 100,000 population among Latino individuals in Connecticut, significantly higher than the rate of 28.2 among Latino individuals nationally, and significantly lower than the rate of 58.2 among white individuals in Connecticut.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 29.7% of lung cancer cases are diagnosed at an early stage among Latino individuals in Connecticut, significantly higher than the rate of 23.1% among Latino individuals nationally, and not significantly different than the rate of 32.9% among white individuals in Connecticut.
- 26.0% of Latino individuals with lung cancer in Connecticut underwent surgery, significantly higher than the rate of 21.6% among Latino individuals nationally, and not significantly different than the rate of 25.1% among white individuals in Connecticut.
- 14.5% of Latino individuals with lung cancer in Connecticut did not receive any treatment, significantly lower than the rate of 26.1% among Latino individuals nationally, and not significantly different than the rate of 17.2% among white individuals in Connecticut.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 24.0 per 100,000 population among Asian or Pacific Islanders individuals in Connecticut, significantly lower than the rate of 32.9 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 58.2 among white individuals in Connecticut.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 24.1% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Connecticut, not significantly different than the rate of 22.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 32.9% among white individuals in Connecticut.
- 28.9% of Asian or Pacific Islander individuals with lung cancer in Connecticut underwent surgery, not significantly different than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 25.1% among white individuals in Connecticut.
- 15.1% of Asian or Pacific Islander individuals with lung cancer in Connecticut did not receive any treatment, not significantly different than the rate of 20.2% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 17.2% among white individuals in Connecticut.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Connecticut due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Connecticut falling into the top tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Connecticut has improved access to expanded screening by covering it through its fee-for-service Medicaid program. The Lung Association encourages all states to cover lung cancer screening based on the latest guidelines across all fee-for-service and managed care plans without any financial or administrative barriers in their Medicaid programs.
Connecticut falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.